Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug 2;2(4):243-7.
doi: 10.1111/j.2040-1124.2011.00131.x.

Pathogenesis of diabetic nephropathy

Affiliations
Review

Pathogenesis of diabetic nephropathy

Zemin Cao et al. J Diabetes Investig. .

Abstract

As the increasing prevalence of diabetes reaches epidemic proportions worldwide, diabetic nephropathy and associated end-stage renal failure will be an unavoidable major health burden to not only individuals with diabetes and their families, but also to the health systems both in developed and developing countries. Over the past decade, a large body of research has focused on diabetic nephropathy ranging from studies in molecular signaling, hemodynamic regulation and pharmaceutical intervention to clinical outcomes. It is likely that the pathophysiology of diabetic nephropathy involves a multifactorial interaction between metabolic and hemodynamic factors. Metabolic factors involve glucose-dependent pathways, such as advanced glycation end-products and their receptors. Hemodynamic factors include various vasoactive hormones, such as components of the renin-angiotensin system. It is likely that these metabolic and hemodynamic factors interact through shared molecular and signaling pathways, such as nuclear factor kappa-light-chain-enhancer of activated B cells and protein kinase C with associated reactive oxygen species generation. It is likely that these contributing factors cause pathological damage not only to the glomerulus, in particular podocytes, but also to the tubulointerstitium. Specific inhibitors of the various pathways are now available and these emerging pharmaceutical interventions might have potential implications for the prevention and treatment of diabetic nephropathy. The mainstay of therapy remains the achievement of optimal glycemic and blood pressure control in order to slow the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system have been shown to be particularly useful as renoprotective agents in both hypertensive and normotensive type 1 and type 2 diabetic subjects. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00131.x, 2011).

Keywords: Angiotensin converting enzyme 2; Cell division autoantigen 1; Reactive oxygen species.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schema of pathogenesis of diabetic nephropathy. The pathogenesis of diabetic nephropathy is likely to be as a result of metabolic and hemodynamic abnormalities, as seen in diabetes, interacting with each other and with various reactive oxygen species‐dependent pathways. Both gene regulation and activation of transcription factors are influenced by the interactions between metabolic stimuli, hemodynamic factors and reactive oxygen species generation in diabetes. The consequences of this molecular activation or inhibition are functional and structural changes leading to the classical hallmarks of diabetic nephropathy. AGE, advanced glycation end‐products; ECM, extracellular protein production; ESRF, end‐stage renal failure; ET, endothelin; GFR, glomerular filtration rate.

Similar articles

Cited by

References

    1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213–219 - PubMed
    1. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–1972 - PubMed
    1. Tikellis C, Bernardi S, Burns WC. Angiotensin‐converting enzyme 2 is a key modulator of the renin‐angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2010; 20: 62–68 - PubMed
    1. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin‐angiotensin system. Trends Endocrinol Metab 2004; 15: 166–169 - PMC - PubMed
    1. Koitka A, Cooper ME, Thomas MC, et al. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 2008; 35: 420–425 - PMC - PubMed